CYMS101 — NDA/BLA submission
in 2026
We plan to file an IND application for a Phase 1/2 clinical trial relating to MS in the United States in 2026 after we receive FDA clearance for our IND relating to CYPS317.Source filing
FBLG biotech catalysts & pipeline
FIBROBIOLOGICS INC · Data as of 2026-09-08
Upcoming catalysts
CYWC628 — Interim data
Q3 2026
We will report six-week interim safety and primary efficacy data of the clinical trial once 28 patients from each of the three arms of the study have completed at least 6 weeks of treatment, which we expect will occur in the third quarter of 2026.Source filing
CYWC628 — other
Q3 2026
Based upon our progress to date, we expect to initiate our twelve-week Phase 1/2 clinical trial utilizing CYWC628 for treatment of diabetic foot ulcers in Australia in the first quarter of 2026 and we expect to complete the clinical trial in the third quarter of 2026.Source filing
CYWC628 — Topline data
Q4 2026
We plan to report the final primary safety and efficacy data of the study once all the continuously enrolled patients that remain in all arms of the study have completed at least 12 weeks of treatment, which we expect will occur in the fourth quarter of 2026.Source filing
CYWC628 — Full data
Q3 2027
We expect to release the final report of the study, which will include all the primary and secondary outcomes outlined in the clinical trial, in the third quarter of 2027.Source filing